Evidence map›Paper›PMID 40160323›Full record

SynthesisFrontiers in medicine2025

Anticoagulation quality through time in therapeutic range in Sub-Saharan Africa: a systematic review and meta-analysis.

Desalegn Getnet Demsie, Zenaw Debasu Addisu, Chernet Tafere, Kebede Feyisa, Bereket Bahiru, Malede Berihun Yismaw, Getahun Mihret, Abere Tilahun, Desye Gebrie, Derbew Fikadu Berhe

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Desalegn Getnet DemsieDepartment of Pharmacy, College of Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.
Zenaw Debasu AddisuDepartment of Pharmacy, College of Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.
Chernet TafereDepartment of Pharmacy, College of Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.
Kebede FeyisaDepartment of Pharmacy, College of Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.
Bereket BahiruDepartment of Pharmacy, College of Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.
Malede Berihun YismawDepartment of Pharmacy, College of Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.
Getahun MihretDepartment of Neurology, St. Peter Hospital, Addis Ababa, Ethiopia.
Abere TilahunDepartment of Anesthesia, College of Medicine and Health Sciences, Adigrat University, Adigrat, Ethiopia.
Desye GebrieDepartment of Pharmacy, College of Medicine and Health Sciences, Woldia University, Woldia, Ethiopia.
Derbew Fikadu BerheDepartment of Pharmacology, Biomedical Division, and Center for Equity in Global Surgery, University of Global Health Equity, Kigali, Rwanda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The quality of anticoagulation with warfarin is often assessed through the time in therapeutic range (TTR). However, achieving optimal TTR and maintaining therapeutic INR levels presents significant challenges in Sub-Saharan Africa. This review aims to summarize the existing evidence on the quality of warfarin anticoagulation among patients in Sub-Saharan Africa. Method: We searched MEDLINE via Ovid, PubMed, Embase via Ovid, and Scopus, and citation analysis from Google Scholar. The review's primary focus was therapeutic INR and TTR ≥ 65. Meta-analysis was conducted using R version 4.3.3. A mixed-effects meta-regression model was used to examine the influence of moderators, with heterogeneity estimated using Results: We identified 15 observational studies for inclusion in this systematic review and meta-analysis. Egger's test confirmed an absence of publication bias across these studies. Sensitivity analyses showed consistency in individual therapeutic INR (pooled estimate: 0.37; range: 0.37-0.40) and TTR (pooled estimate: 0.16; range: 0.15-0.17), closely aligning with pooled proportions. Meta-analysis of high-quality TTR measurements yielded a pooled prevalence of 17% ( Conclusion: Warfarin therapy is associated with very low percentage of TTR suggests poor quality of anticoagulation management. Sensitivity analyses confirmed the robustness of these findings.

Indexed as

anticoagulationINRSub-Sahara AfricaTTRwarfarin

Identifiers

PMID40160323
PMCPMC11949880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.